Clinical trials: Helicobacter
Bacterial Infection Due to Helicobacter Pylori (H. Pylori), Peptic Ulcer Bleeding
Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding
Low-dose aspirin (ASA) has emerged as the most important cause of peptic ulcer bleeding worldwide. In western countries, ASA has overtaken non steroidal antiinflammatory drugs (NSAIDs) as a major cause of peptic ulcer bleeding in…
- Trial name
- 2NA3NANC (NCT01591486)
- Where
- China
- Volunteers
- 904 people
- Sponsor
- Chinese University of Hong Kong
Helicobacter Pylori Infection
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication
The aim of this randomized trial is to compare the efficacy and tolerability of H. pylori eradication with a 5-day quadruple therapy versus a clarithromycin-containing triple therapy.
- Trial name
- NCT01306786
- Testing
- Quadruple therapy, Triple therapy
- Where
- Hong Kong
- Volunteers
- 800 people
- Sponsor
- The University of Hong Kong
Helicobacter Pylori
Helicobacter in The Gambia (Part 1)
H. pylori infection causes the stomach to become inflamed. The problem usually begins in childhood and leads to stomach problems in adult life.
- Trial name
- NCT00466700
- Where
- The Gambia
- Volunteers
- 75 people
- Sponsor
- Medical Research Council Unit, The Gambia
Helicobacter Infected Patients
Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial
The purpose of this study is to improve first line Helicobacter pylori eradication rate and to compare the sequential versus conventional triple therapy.
- Trial name
- NCT01418300
- Testing
- sequential versus triple
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Jun-Won Chung
Dyspepsia, Helicobacter-associated Gastritis
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients.
- Conditions
- Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders
- Trial name
- NCT01888237
- Testing
- Double dose of PPI, sequence of drug use
- Where
- Thailand
- Volunteers
- 118 people
- Sponsor
- Mahidol University
Helicobacter Infections
Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
Clinical trial to compare efficacy on eradicating Helicobacter pylori with two antibiotic strategies: sequential with amoxicillin and omeprazole 5 days and clarithromycin with metronidazole and omeprazole 5 days or omeprazole…
- Trial name
- NCT02395458
- Testing
- Sequential therapy, Triple therapy
- Volunteers
- 142 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Helicobacter Pylori Infection
Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection
New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been successfully introduced into the treatment of Helicobacter…
- Trial name
- NCT02368470
- Testing
- Gemifloxacin-based triple therapy, Standard triple therapy
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Samsung Medical Center
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
POCone-UBiT-IR300 Pediatric Comparison Study
The purpose of this study is to compare between the POCone® to the UBiT®-IR300 in measuring 13CO2/12CO2 ratio in breath samples when used together with the BreathTek® UBT (urea breath test) Kit and the pUHR-CA web-based software…
- Trial name
- NCT01623154
- Testing
- Pranactin citric solution
- Where
- 3 sites in United States
- Volunteers
- 99 people
- Sponsor
- Otsuka America Pharmaceutical
Eradication Rate for Helicobacter
Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy
To compare the efficacy and tolerability of levofloxacin-based sequential therapy and triple therapy in the second line therapy for those who fail from one eradication therapy
- Trial name
- NCT01537055
- Testing
- levofloxacin-based sequential therapy, levofloxacin-based triple therapy for 10 days
- Where
- 10 sites in Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
HELICOBACTER INFECTION
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
Helicobator pylori (H. pylori) is a bacteria which survives in the lining of the stomach. An estimated 50% of the world's population is infected with H. pylori.
- Trial name
- NCT02051348
- Testing
- Pylopass
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Positivity for Helicobacter Pylori
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
Background and Aims H.pylori is a common human pathogen by which almost 50% of the world population is infected. According to the accepted guidelines, once H.pylori infection has been diagnosed,first line therapy with three drugs…
- Trial name
- CurHP (NCT02018328)
- Testing
- Curcumin
- Where
- 2 sites in Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Gingold Belfer Rachel
Helicobacter Pylori Infection
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurrence of these diseases.
- Trial name
- NCT02249546
- Testing
- N-acetylcysteine + PPI-amoxicillin-clarithromycin, PPI-amoxicillin-clarithromycin
- Where
- 2 sites in Taiwan
- Volunteers
- 654 people
- Sponsor
- National Taiwan University Hospital
Cure Rate of Helicobacter Pylori Infection
Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
To test the efficacy of 14 day levofloxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.
- Trial name
- NCT01742429
- Testing
- Proton pump inhibitor, Bismuth subsalicylate, Metronidazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Triple therapy (TT) comprising proton pump inhibitor (PPI), amoxicillin 1g and clarithromycin 500mg twice daily has long been considered one of the standard treatment for H.
- Trial name
- NCT02092506
- Testing
- 10 day triple therapy, 10 day sequential therapy, 10 day concomitant therapy
- Where
- Singapore
- Volunteers
- 462 people
- Sponsor
- Changi General Hospital
Helicobacter Pylori Infection
Anti-H. Pylori Effect of Deep See Water
Deep sea water (DSW) is characterized by high purity, low temperature, high nutrients and minerals and is obtained from the water flows 200 meters under the surface of the sea. The inhibition of H.
- Trial name
- NCT01933659
- Testing
- DSW
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Infections
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
H. pylori infection is the most important causative agent of gastritis, and subsequent atrophic gastritis. The endoscopic diagnosis of H. pylori infection relies on urease tests such as the Clo test.
- Trial name
- NCT02126722
- Testing
- Gastroscopy, EndoFaster test, Clo test
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Niso Biomed S.R.L.
HELICOBACTER PYLORI INFECTIONS
Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections
The investigators hypothesis: Presence of anti-GGT (antibody against GGT) indicates H. pylori infection.
- Trial name
- NCT02123771
- Where
- Singapore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Helicobacter Infections
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
The proposed study will test the hypothesis that H. pylori can be eradicated successfully (>85%) using half-or full-dose "concomitant" non-bismuth quadruple therapy regimen: rabeprazole, amoxicillin, clarithromycin and…
- Trial name
- NCT01219764
- Testing
- Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
- Where
- Lebanon
- Volunteers
- 200 people
- Sponsor
- American University of Beirut Medical Center
Helicobacter Pylori Infection
Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection
Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H.
- Trial name
- NCT01643785
- Testing
- Second-line quadruple therapy with endonase
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chuncheon Sacred Heart Hospital